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-Lactamases and penicillin-binding proteins (PBPs) have evolved from a common ancestor. -Lactamases are enzymes that
degrade-lactam antibiotics, whereas PBPs are involved in the synthesis and processing of peptidoglycan, which forms an elas-
tic network in the bacterial cell wall. This study analyzed the interaction between -lactamases and peptidoglycan and the im-
pact on fitness and biofilm production. A representative set of all classes of -lactamases was cloned in the expression vector
pBGS18 under the control of the CTX-M promoter and expressed in Escherichia coliMG1655. The peptidoglycan composition of
all clones was evaluated, and quantitative changes were found in E. coli strains expressing OXA-24, OXA-10-like, and SFO-1
(with its upstream regulator AmpR) -lactamases; the level of cross-linkedmuropeptides decreased, and their average length
increased. These changes were associated with a statistically significant fitness cost, which was demonstrated in both in vitro and
in vivo experiments. The observed changes in peptidoglycan may be explained by the presence of residual DD-endopeptidase ac-
tivity in these-lactamases, which may result in hydrolysis of the peptide cross bridge. The biological cost associated with these
changes provides important data regarding the interaction between -lactamases and the metabolism of peptidoglycan andmay
provide an explanation for the epidemiology of these -lactamases in Enterobacteriaceae.
Antibiotic resistance is currently one of the main problems inpublic health. The most widespread and threatening mecha-
nism of antibiotic resistance is the production of -lactamases,
enzymes that degrade -lactam antibiotics. -Lactamases exhibit
diversity in both structure and function. The simplest classifica-
tion (described by Ambler), based on the protein sequence, di-
vides-lactamases into fourmolecular classes (A toD) (1).Mem-
bers of classes A, C, and D are serine-dependent enzymes, while
members of class B are metalloenzymes that use zinc to facilitate
-lactamase hydrolysis. Moreover, the classification scheme de-
scribed Bush and Jacoby (13), which is based on functional simi-
larities (assessed by substrate and inhibitor profile), is of greater
significance to physicians and microbiologists in diagnostic labo-
ratories because it considers clinically relevant -lactams and in-
hibitors.
The targets of -lactam antibiotics are penicillin-binding pro-
teins (PBPs). PBPs are involved in the synthesis and processing of
peptidoglycan (PG) (41), which forms an elastic network in the
cell wall. The main functions of this network are to resist the
intracellular pressure of the cell and to maintain a defined cell
shape (44).
All -lactamases and PBPs evolved from a common ancestor,
the primordial PBP, in independent and perhaps parallel pro-
cesses (27), and each is specialized in different functions; PBPs
display transpeptidase, carboxypeptidase, or endopeptidase activ-
ity (41), and -lactamases inactivate -lactam antibiotics by hy-
drolyzing the -lactam ring. However, PBP5 from Pseudomonas
has been described as a weak -lactamase (23). Conversely, mu-
tation of certain PBPs modifies the expression of -lactamases
(such as PBP4 and AmpC in Pseudomonas aeruginosa) (32). The
AmpC-type -lactamase fromCitrobacter has also been suggested
to display residual DD-carboxypeptidase activity in vivo, with an
effect on fitness when expressed in Salmonella (31). The interac-
tion between resistance mechanisms and bacterial fitness is a sub-
ject of increasing interest. The effect of these mechanisms on fit-
ness is a key parameter for evaluating the epidemiological
implications for a givenmicroorganism, which depend on its abil-
ity to persist in bacterial populations once the selective pressure
exerted by antibiotics disappears.
Measurement of bacterial fitness competition between bacteria
expressing different -lactamases provides a sensitive method for
detecting phenotypic differences (34). Furthermore, the acquisi-
tion of plasmids with antibiotic resistance genes may have several
effects on bacterial fitness (2, 25). Hence, the objectives of the
present study were (i) to determine the interaction between the
expression of -lactamases and the composition and/or structure
of PG and (ii) to analyze the influence of these changes in PG on
fitness and biofilm formation.
MATERIALS AND METHODS
-Lactamases: cloning experiments and determination of specific ac-
tivity. A set of isogenic clones expressing representative members of all
classes of -lactamases was constructed (Table 1). All -lactamases were
cloned between BamHI and EcoRI restriction sites into the pBGS18-pCT
vector (pB) under the control of a blaCTX-M promoter, an expression
vector harboring a kanamycin resistance gene. Escherichia coliwas chosen
as an Enterobacteriaceae model for further studies. The E. coli MG1655
(MG) (14) electrocompetent strains were transformedwith these plasmid
constructions. To confirm the accuracy of the nucleotide sequences, all
cloned genes were sequenced following standard procedures.
To study the specific activity, the bacterial strains were grown over-
night in 50 ml of Luria-Bertani (LB) broth at 37°C with shaking. The cells
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were harvested by centrifugation, washed once with potassium-sodium
phosphate (phosphate-buffered saline [PBS]), and resuspended in 1ml of
the same buffer. To obtain the cell extract, cells were broken by ultrasonic
treatment at 4°C. Cell debris was removed by centrifugation at 10,000 rpm
for 10min. The specific enzyme activity of each extract was determined by
measuring the hydrolysis of a 100 M nitrocefin solution prepared in
dimethyl sulfoxide (DMSO), monitored at 25°C, in a spectrophotometer
at a wavelength of 485 nm. Protein concentration was measured by the
Bradford method (11).
Peptidoglycan analysis. PGwas purified from bacterial cells grown in
LB broth to an optical density at 600 nm (OD600) of 1. We added imi-
penem, at a concentration of 0.06 g/ml (ca. 1/4 of the MIC), at the
beginning of the culture. The bacteria were collected, suspended in 3ml of
PBS, mixed immediately in a 1:1 (vol/vol) proportion with a boiling so-
lution of 10% sodiumdodecyl sulfate (SDS) (Bio-Rad), andmaintained at
100°C for 18 h. The SDS-insoluble material, containing PG, was washed
until it was free of SDS by successive suspensions in distilled water and
centrifuged at high speed at room temperature. PG was treated with
-amylase (100 g/ml) at 37°C for 90 min and with pronase E (100 g/
ml) at 60°C for 60 min. The reaction was stopped by adding SDS and
boiling the mixture for 20 min. The PG was further digested in 50 mM
phosphate buffer (pH 4.9) with Cellosyl (Hoechst AG, Frankfurt, Ger-
many) at a 100-g/ml final concentration at 37°C overnight. The insolu-
ble material was removed by centrifugation, and soluble muropeptides
were reduced with sodium borohydride and frozen at70°C. The mura-
midase-digested samples were analyzed by high-performance liquid chro-
matography (HPLC) as previously described (43). The subunits which
comprise the polymer murein and were resolved by HPLC have been
described previously (19, 44). The basic disaccharide peptide subunit
(monomer) consists of -1,4-linked GlcNAc andMurNAc with a peptide
stem of three, four, or five residues. Cross-linked monomers with a single
bond are dimers, and those with two bonds are trimers. Monomers,
dimers, and trimers ending with a 1,6-anhydro-MurNAc residue are
termed anhydro, and they correspond to chain ends. Subunits having a
peptide bond with the Lpp protein are termed Lpp. Pentapeptides are any
subunit having a five-residue peptide stem. Glycan strand chain length
(chain length) was calculated as the inverse of the total proportion of
anhydro muropeptides. Cross-linking was calculated as the percentage of
dimers or trimers (2) in relation to the total amount of muropeptides.
In some cases (MGalone andMGwith the TEM-1, VIM-1, AmpR-SFO-1,
OXA-10-like, and OXA-24 -lactamases), experiments were also done
without imipenem (see Table 2).
TEM. For analysis by transmission electron microscopy (TEM), the
strains with the different plasmid constructions were cultured overnight
in the presence of 0.06g/ml of imipenem. Cells were then harvested and
resuspended in 4% cold glutaraldehyde diluted in 0.1M phosphate buffer
(pH 7.4), allowed to stand for 30 min at room temperature, and fixed in
1% osmium tetroxide in the same buffer for 1 h at 4°C. Pellets were then
dehydrated in an acetone gradient and embedded in Spurr resin.Ultrathin
sections (70 nm) were examined and photographed using a JEOL JEM
1010 TEM (80 kV).
Bacterial growth.All bacterial strains were grown in LB broth at 37°C
and 180 rpm. Growth was monitored by measuring the OD600. The
growth rate () was calculated on the basis of the exponential segment of
the growth curve and defined as ln2 g
1, where g is the doubling time of an
exponentially growing culture (3). Experiments were done in triplicate.
TABLE 1 -Lactamases expressed in this study
B-lactamase
Ambler
class Hydrolysis antibiotics
Host(s) most
frequently
encountered Reference(s)
Oligonucleotide sequences used for cloning
(5=¡ 3=)a
TEM-1 A Penicillins, early
cephalosporins
Escherichia coli 8, 12 F, ggatccATGAGTATTCAACATTTTCGTGTC; R,
gaattcTTACCAATGCTTAATCAGTGAGG
TEM-29 A ESBLb E. coli and Klebsiella
pneumoniae
8, 12 F, ggatccATGAGTATTCAACATTTCCGTGT; R,
gaattcTTACCAATGCTTAATCAGTGAGG
CTX-M-32 (cluster 1) A ESBL (100-fold more active
against ceftazidime than
the other CTX-Ms)
Enterobacteriaceae 15, 24, 35 F, ggatccATGGTTAAAAAATCACTGCGTCA; R,
gaattcTTACAAACCGTTGGTGACGAT
CTX-M-8 (cluster 8) A ESBL Enterobacteriaceae 6, 24, 35 F, ggatccATGATGAGACATCGCGTTAAG; R,
gaattcTTAATAACCGTCGGTGACGAT
CTX-M-2 (cluster 2) A ESBL Enterobacteriaceae 24, 35; this
work
F, ggatccATGATGACTCAGAGCATTCG; R,
gaattcTCAGAAACCGTGGGTTACG
CTX-M-14 (cluster 9) A ESBL Enterobacteriaceae 7, 24, 35 F, ggatccATGGTGACAAAGAGAGTGCAA; R,
gaattcTTACAGCCCTTCGGCGAT
SFO-1 A ESBL Enterobacter cloacae 16, 28 F, ggatccATGGTTAAAAATACATTACGTCAAAC; R,
gaattcTCAAAGCCCTTCGGTGACAA
AmpR-SFO-1 A ESBL Enterobacter cloacae 16, 28 F, ggatccCTACGTATTATCTTCTGCCGC; R,
gaattcTCAAAGCCCTTCGGTGACAA
VIM-1 B Most -lactams, except
aztreonam, including
carbapenems
Pseudomonas,
Enterobacteriaceae
30, 45 F, ggatccATGTTAAAAGTTATTAGTAGTTTATTGG
R, gaattcCTACTCGGCGACTGAGC
FOX-4 C Penicillins, narrow-,
expanded-, and broad-
spectrum
cephalosporins,
including cephamycins
Enterobacteriaceae 10, 20, 26 F, ggatccATGCAACAACGACGTGCG; R,
gaattcTCACTCGGCCAACTGACTC
OXA-10-like D Oxacillin, cloxacillin Pseudomonas
aeruginosa
12; this work F, ggatccATGAAAACATTTGCCGCATATGTA; R,
gaattcTTAGCCACCAATGATGCCCT
OXA-24 D Oxacillin, cloxacillin,
carbapenems
Acinetobacter
baumannii
9, 29 F, ggatccATGAAAAAATTTATACTTCCTATATTCA;
R, gaattcTTAAATGATTCCAAGATTTTCTAGCG
a F, forward; R, reverse. Lowercase indicates target site for restriction enzymes.
b ESBL, hydrolysis profile that confers resistance to the penicillins, broad-spectrum cephalosporins, and monobactams but not the cephamycins or carbapenems.
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In vitro competition experiments (in vitro fitness). Experiments
were performed tomeasure the in vitro competition between -lactamase
clones and E. coli MG1655 with the pBGS18-pCT vector [MG(pB)]. Ex-
ponentially growing cells of the corresponding transformant and control
strain were mixed in a 1:1 proportion and resuspended in 0.9% saline
solution. Approximately 103 cells from eachmixture were inoculated into
10-ml flasks of LB broth and grown at 37°C and 180 rpm for 16 to 18 h,
which corresponds to approximately 20 cell generations. Serial 10-fold
dilutions were plated in duplicate onto LB agar (LBA) with 50 g/ml of
kanamycin (LBA-K) and LBAwith 50g/ml of kanamycin and ampicillin
(LBA-K/A) in order to determine, respectively, the total number of CFU
and the CFU of the clones harboring -lactamases, after overnight incu-
bation at 37°C. The competition index (CI) was defined as the ratio be-
tween the CFU of the strain harboring a -lactamase and the MG(pB)
strain. The CI values were calculated for each independent competition
assay, and themedian values were calculated too. Statistical analysis of the
distribution of the CI values was performed with the Mann-Whitney U
test. Differences were considered statistically significant at a P value of
0.05 (33).
Fitness in themousemodel of systemic infection (in vivo fitness). In
vivo fitness was assessed by competition experiments with a mouse model
of systemic infection. For this purpose, mixtures of each of the strains
containing approximately 5 106 exponentially growing cells were inoc-
ulated intraperitoneally into five female C54 mice, of about 18 to 20 g in
weight, previously treatedwith cyclophosphamide (100mg/kg) for 3 days.
The mice were sacrificed at 24 h after inoculation, and their spleens were
aseptically extracted and homogenized in 1ml of 0.9% saline solution in a
Retsch MM200 mixer mill. The number of CFU of each strain and the CI
values were determined as described for in vitro competition experiments.
Static biofilm assays. Static assays of biofilm formation, by determin-
ing adherence to polystyrene, were performed as described previously
(39) with somemodifications. Isolates of E. coliwere grown overnight in 5
ml LB broth (37°C, 180 rpm). After overnight incubation, E. coli cultures
were standardized to an optical density of 0.2 at 600 nm. All standardized
cultures were inoculated 1/20 in 150 l of M9 with glucose (0.2%) in a
96-well polystyrene microtiter plate (U bottom; Soria Genlab S.A.) Test
plates were transferred to plastic bags to avoid evaporation of medium
and incubated at 37°C for 48 h without shaking. Eight wells were inocu-
lated for each strain. After removal of planktonic cells, the wells were
rinsed with 0.9% sodium chloride and biofilms were stained with 200 l
of 0.2% crystal violet (CV). After 15 min, the plate was rinsed with 0.9%
sodium chloride. The amount of biofilm formed in each well was deter-
mined spectrophotometrically after solubilization of theCV retainedwith
200l of an 80:20mixture of ethyl alcohol and acetone. The absorbance of
CV was measured at 570 nm in an automated 96-well plate reader.
RESULTS
Clones carrying the different -lactamases were obtained (Table
2); MG carrying pB, without any -lactamase, was used as a neg-
ative control. Although the OXA-10-like enzyme has two amino
acid changes compared to the wild-type OXA-10 (Met99Tyr and
Gly212Met), kinetic parameters, such as Kcat and Km, toward am-
picillin and oxacillin were the same for the OXA-10-like enzyme
and wild-type OXA-10 (data not shown). No imipenem hydroly-
sis was detected with this OXA-10-like variant. The relative spe-
cific activities of MG carrying pB-AmpR-SFO-1 or pB-SFO-1
against nitrocefin were 520 9 mol min1 mg1 and 140 16
mol min1 mg1, respectively. The results revealed higher hy-
drolytic activity against nitrocefin when the SFO-1--lactamase
gene was cloned with the upstream ampR gene (pB-AmpR-SFO-1
construction), which is consistent with previous findings (28).
The expression of all -lactamases was checked by determina-
tion of theMICs of specific antibiotics, which depend on the char-
acteristic hydrolytic profile of each-lactamase. All clones showed
appropriate susceptibility antibiotic profile according to previ-
ously reported data, thus demonstrating proper expression of
all -lactamases. Imipenem MICs were identical with all strains
TABLE 2Muropeptide compositions of peptidoglycans from E. coliMG1655 carrying pBGS18-pCT (plasmid alone, control strain) and different
-lactamasesa
Sampleb
Relative abundance (mol%)c
Cross-linkage (%) Chain lengthMonomers Dimers Trimers Lpp Anhydrous forms Pentapeptides
MG(pBGS18-pCT) 61.0 0.8 36.1 0.8 2.9 0.1 18.0 0.4 8.6 1.4 0.3 0.2 42.0 0.9 11.9 2
MG(pBTEM-1) 62.9 2.8 34.9 3.2 2.8 0.3 16.1 2.9 8.4 1.1 0.8 0.06 40.5 3.7 12 1.5
MG(pBTEM-29) 62.8 2.6 33.5 3.4 3.8 0.8 14.8 4.1 10.9 1.1 0.5 0.02 41.1 1.8 9.2 0.9
MG(pBCTX-M-32) 63.1 0.2 34 0.3 2.7 0.03 14.1 0.9 7.0 0.04 0.2 0.02 39.6 0.1 14.3 0.07
MG(pBCTX-M-8) 64 0.4 33.6 0.5 2.4 0.03 13.1 1.8 5.4 0.3 0.23 0.01 38.4 0.4 18.3 1.0
MG(pBCTX-M-2) 63.3 0.5 33.7 0.4 2.9 0.9 14.9 1.7 6.4 0.2 0.3 0.1 39.7 1.3 15.7 0.5
MG(pBCTX-M-14) 62.5 0.5 34.8 0.3 2.7 0.2 15.6 2.1 6.9 0.7 0.1 0.001 40.3 0.7 14.7 1.5
MG(pBSFO1) 61.3 1.3 35.1 0.7 3.7 0.6 15.4 0.9 12.1 3 0.5 0.3 42.4 1.9 8.8 2.8
MG(pBAmpR-SFO1) 68.7 0.2 29.4 0.2 1.9 0.02 12.7 0.01 3.3 0.1 0.1 0.02 33.3 0.2 29.8 1.2
MG(pBVIM-1) 61.2 2.1 35.8 1.5 2.9 0.6 15.5 2.3 6.4 1.0 0.2 0.1 41.8 2.7 15.9 2.5
MG(pBFOX-4) 63.7 0.5 33.8 0.7 2.4 0.2 12.2 1.6 5.8 0.1 0.3 0.04 38.6 0.4 17.2 0.3
MG(pBOXA-10-like) 65.9 0.1 31.8 0.1 2.3 0.02 12.2 0.1 4.9 0.8 0.2 0.2 36.3 0.1 20.7 3
MG(pBOXA-24) 68.9 1 28.8 0.9 2.2 0.2 12.2 2.3 3.6 0.2 0.1 0.03 33.3 1.2 28.1 0.5
MG(pBGS18-pCT)d 69.5 0.7 28.3 0.6 2.3 0.12 11.8 1.35 4.3 0.1 0.1 0.1 32.8 0.8 23.4 0.7
MG(pBTEM-1)d 68.1 0.2 29.4 0.4 2.5 0.2 13.3 0.6 4.9 0.3 0.1 0.1 34.4 0.1 20.5 1.2
MG(pBAmpR-SFO1)d 69.1 1.6 28.7 1.5 2.3 0.2 12.1 1.3 4.9 0.7 0.1 0.04 33.2 1.8 20.5 2.8
MG(pBVIM-1)d 69.2 1.0 28.4 0.6 2.35 0.4 11.9 0.9 4.5 1.8 0.1 0.01 33.2 1.3 20.1 3.7
MG(pBOXA-10-like)d 74.2 5.9 25.9 2.8 2.4 0.5 11.6 0.6 4.8 2.2 0.07 0.01 32.6 0.8 21.5 3.5
MG(pBOXA-24)d 69.2 0.8 28.5 0.5 2.3 0.3 9.9 3.0 3.8 0.2 0.2 0.1 33.1 1.1 26.5 1.2
a Values are means and standard deviations from three independent experiments. Boldface indicates the isolates in which changes in the PG composition have been described.
b Peptidoglycan of E. coliMG1655 transformed with the indicated plasmid.
c Muropeptides are grouped according to structural similarities, differences in PG composition, and structure of strains.
d Data were obtained without the presence of imipenem.
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(0.25 g/ml) except MG expressing the VIM-1 and OXA-24
-lactamases, which showed a 1-dilution increase in MIC.
Effect of-lactamase production on E. coli PG composition.
The steady-state length distribution of glycan strands in E. coli is
extremely broad and depends on the strain, conditions, and
growth phase (44). Representative -lactamases of all classes were
therefore cloned into a vector with identical genetic environment,
and extraction and analysis of PGwere performed under identical
experimental conditions in three independent experiments. The
PG compositions of E. coli producing different -lactamases are
detailed in Table 2.
No major qualitative differences were found in the PG from
any of the strains harboring different -lactamases. However,
some quantitative changes in MG1655 strains carrying pB-OXA-
10-like, pB-OXA-24, and pB-AmpR-SFO-1 were found, showing
a decrease in the levels of dimers and trimers, anhydrous muro-
peptides, and pentapeptides and an increase in monomers and
lipoprotein-bound muropeptides (Table 2). In addition, the level
of cross-linked muropeptides decreased and the average length
increased in these strains. The muropeptide compositions of PG
in the remaining strains were almost identical to that of the con-
trol E. coli MG1655 with pBGS18-pCT vector [MG-(pB)]. For
comparative purposes, data for with MG1655 expressing the
TEM-1, OXA-10-like, VIM-1, AmpR-SFO-1, and OXA-24 en-
zymes without imipenem are also shown (Table 2).
TEM. Transmission electron microscopy (TEM), in which an
electron beam is passed through ultrathin sections and produces
an image of the sample, has been used to investigate the effects of
antibiotics on the cell wall, and morphological and structural
changes have been observed (42). The morphologies of MG1655
strains carrying recombinant vectors pB-AmpR-SFO-1, pB-OXA-
10-like, pB-OXA24, and pBGS18-pCT were analyzed by TEM.
Despite the quantitative compositional changes in the PGs of
these strains, it was not possible to observe any ultrastructural
changes in the cell wall by TEM (Fig. 1).
Growth curves. A growth curve experiment was performed to
assess the growth rates under noncompetitive conditions and
therefore to check the effects of carrying the plasmids on the E. coli
growth rate. The curve patterns were similar for all strains (Fig. 2).
All strains showed a similar growth rate (), with values ranging
from 0.021 to 0.023, regardless of the expressed -lactamases.
In vitro competition experiments (in vitro fitness). In an
FIG1 Transmission electronmicroscopy analysis ofE. coliMG1655 strains harboring pBOXA-10-like and pBAmpR-SFO1 recombinant plasmids and of control
strain MG(pBGS18-pCT).
FIG 2 Growth curves for E. coliMG1655 harboring different-lactamases in LBmedium.Data aremean values of threemeasurements. For simplification, error
bars have been omitted, although in all cases the standard deviation was10%.
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antibiotic-free environment, bacterial strains carrying plasmids
harboring resistance genes compete with those strains that do not
possess such resistance genes. The outcome of the competition
process depends on the relative fitness, defined as the efficacy
of multiplication of the resistant cell compared with that of the
susceptible cell. The presence of plasmids encodingCTX-M-lac-
tamases, such as pB-CTX-M-32 and pB-CTX-M-8, pB-TEM-1,
pB-VIM-1, and pB-FOX-4, was not associated with a significant
fitness cost with respect to E. coli MG(pB) in vitro. However, we
observed a marked and statistically significant decrease in fitness
competition for E. coli MG1655 carrying recombinant plasmids
pB-AmpR-SFO-1, pB-OXA-10-like, and pB-OXA-24, as shown
by the competition index (CI) results in Fig. 3 (P  0.05 in all
cases). The greatest decrease was observed for the MG(pB-OXA-
10-like)/MG(pB) competition, with a median CI of 0.3, followed
by the MG(pB-OXA-24)/MG(pB) and MG(pB-AmpR-SFO-1)/
MG(pB) competitions, with median CIs of 0.43 and 0.55, respec-
tively.
It is remarkable that those -lactamases that showed changes
in the quantitative composition of PG were clearly and directly
associated with a reduction in fitness cost (Table 2 and Fig. 3).
Overall, the data showed that the median CI values for the
MG1655 strains carrying plasmids pB-AmpR-SFO-1, pB-OXA-
10-like, and pB-OXA-24 were associated with a statistically signif-
icantly decreased fitness in the in vitro experiments.
Fitness in the mouse model of systemic infection (in vivo
fitness). Since results obtained in vitro and in vivo do not always
correspond and since an animal model is much closer to what
occurs in the human body at the infection site, we assessed the
competition assays in a mouse model of systemic infection. The
results were similar to those obtained in vitro (Table 3). MG(pB-
OXA-10-like) and MG(pB-AmpR-SFO-1) were associated with a
significantly increased (P  0.001) biological cost, and MG(pB-
TEM-1) and MG(pB-SFO-1) did not show any biological cost
effect since fitness was the same as in theMG(pBGS18-pCT) con-
trol strain. In the case ofOXA-24, an effect similar to that obtained
in the in vitro assays was observed (data not shown). It is impor-
tant to emphasize that the effect on biological cost obtained with
SFO-1 with its upstream AmpR regulator is abrogated when the
-lactamase gene lacks its AmpR positive regulator, thus demon-
strating that the effect is directly related to the -lactamase gene
expression.
Biofilm production. In order to assess whether the changes in
PG composition had any effect on biofilm formation, those strains
in which changes in PG composition had been observed were
assayed for biofilm formation. All the studied strains formed less
biofilm than the control strain carrying the pBGS18-pCT vector
(Fig. 4).
DISCUSSION
Understanding the physiological basis of fitness costs in isolates
carrying-lactamases is clinically relevant, since-lactams are the
most frequently used treatment for bacterial infections and -lac-
tamases constitute themainmechanismof resistance to-lactams
in Gram-negative bacilli. The main aim of this study was to assess
biological changes in PG composition in members of Enterobac-
teriaceae expressing -lactamases in relation to their fitness. In
this respect, there is some information on changes in the PG com-
FIG 3 Results of in vitro competition experiments. The CI values obtained for each of the eight independent experiments are plotted, with the median CI values
shown by horizontal lines.
TABLE 3 Results of in vivo competition experiments in the mouse
model of systemic infection
Competition Median CI (range)
TEM-1/pBGS18 1.15 (1.01–1.35)
SFO-1/pBGS18 1.08 (0.8–1.5)
AmpR-SFO1/pBGS18 0.3 (0.2–0.51)a
OXA-10–like/pBGS18 0.32 (0.25–0.68)a
a Significant (P 0.001).
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position of Salmonella strains producingAmpCand their effect on
virulence (31), although their relationship to fitness has not been
described. It is difficult to address this topic because of the diver-
sity of genetic factors, whichmay affect the final result. The exper-
iments presented here were therefore performed on isogenic
strains and under identical conditions, so that the results reflect
the precise relationship between -lactamases, PG composition,
and fitness.
An effect of -lactamases on PG composition was observed
when imipenem was added at subinhibitory concentrations. This
low imipenem concentration was sufficient to increase the sensi-
tivity of the assay induced by the expression of-lactamases and to
observe its effect on PG composition. As a consequence, the inter-
action between different-lactamases and PGwasmagnified, and
changes were observed when the recombinant strains carrying
-lactamases were compared with the E. coli control strain with-
out any -lactamase.
The binding of the cell wall donor strand (-D-Ala-D-Ala) to the
active-site serine of the PBP can be mimicked by the interactions
of-lactams with the same enzymes. Therefore, the-lactamases,
which bind the -lactam antibiotics, could also bind the donor
strand of the cell wall analogously to a DD-peptidase. Among all
-lactamases tested, only OXA types and AmpR-Sfo1 yielded any
apparent effect, possibly due to a cell wall donor binding activity,
which could be the explanation for the reduction of cross-linking,
due to the lack of terminal D-Ala that is needed for the cross-
linking. However, a direct DD-endopeptidase activity on the ma-
ture PG or DD-carboxypeptidase activity on the cell wall donor
strand cannot be excluded (41).
Production of the different -lactamases had no apparent ef-
fect on the growth rate of E. coli under the noncompetitive exper-
imental conditions (rich medium, LB broth, and no antibiotics),
with similar growth rates being observed. Competition in vitro
and in a mouse model showed that fitness decreased with the
OXA-type (OXA-10-like and OXA-24) and AmpR-SFO-1 -lac-
tamases. The effect on fitness and on PG composition was ob-
served only when the SFO-1 -lactamase was cloned under the
control of the ampR gene, since greater hydrolytic activity was
detected in strains carrying AmpR-SFO-1 than in clones harbor-
ing only SFO-1. Although the regulation of the AmpR-mediated
expression of AmpC in E. coli seems to be simpler than that de-
scribed in Pseudomonas (21), it is not possible to exclude com-
pletely a putative effect due the presence of AmpR in strain
MG(pB-AmpR-Sfo1), but neither there is any evidence for that.
Therefore, the effect of AmpR must be due essentially to the
increase in expression, acting as an upregulator of SFO-1 -lacta-
mase (28).
These data showed that expression of some OXA-type and
AmpR-SFO-1-lactamases in anE. coli strain entails a fitness cost,
and they also provide some knowledge about potential weakness
of selection of these resistant bacteria when expressing these ge-
netic determinants of antibiotic resistance. The biological cost is
thought to be the main driving force for reduction in the fre-
quency of resistant bacteria in the absence of antibiotics (22).
To our knowledge, no clear explanation has been given as to why
some -lactamases are often isolated from a specific genus, whereas
others are scarcely detected in a specific microorganism. Identifica-
tion of differences in the impacts of different-lactamases expressed
inmembersof theEnterobacteriaceaemayhelp inunderstandingwhy
some-lactamases aremore widespread in someGram-negative ba-
cilli than in others.
While most extended-spectrum -lactamases (ESBLs) have been
found in E. coli,Klebsiella pneumoniae, and other Enterobacteriaceae,
most of theOXA-type ESBLs and carbapenemases have beenmainly
found inP.aeruginosaandAcinetobacter spp.Carbapenem-hydrolyz-
ingOXA-type lactamases are often found inAcinetobacter baumannii
(46), OXA-type lactamases with an extended spectrum in P. aerugi-
nosa, and theOXA-48 carbapenem-hydrolyzing enzyme inmembers
of the Enterobacteriaceae (37). Until now, the only OXA-10-like lac-
tamase described in Enterobacteriaceae was OXA-101 (38). The
SFO-1 -lactamase has been isolated only from Enterobacter cloacae
(16, 28), and because of its plasmid location, it could be transmitted
to other bacteria. To our knowledge, no OXA-24 has so far been
described in Enterobacteriaceae.
The SFO-1 is the only class A -lactamase with the ampR gene
upstream (28). Few reports have described codified class C plas-
mids (4, 17, 36, 40) with the upstream ampR gene acting to induce
expression.With all these data, it could be interesting to propose a
hypothesis in which the low dissemination of these enzymes in
FIG 4 Effects of -lactamases on biofilm formation. Static biofilm formation by E. coliMG1655 on polystyrene is shown. Results are themean values from eight
experiments in the presence of 0.06 g/ml imipenem.
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Enterobacteriaceaemay be related to their effects on changes in PG
and therefore to the decrease in fitness.
Although resistance traits encoded by plasmids are usually as-
sociated with a fitness cost (5), we observed that some -lacta-
mases did not affect fitness, which means that this relationship
depends on the type of-lactamase expressed, at least as assayed in
our isogenic model. Hypothetically and based on the decrease in
biological fitness caused by OXA-10-like, OXA-24, and AmpR-
SFO-1 -lactamases in the absence of antibiotics, the strains ex-
pressing these enzymes probably would not be able to dominate
the bacterial population. According to the above-described hy-
pothesis, in the absence of antibiotics these strains will be dis-
placed and the frequency of isolation will be lower. Interestingly,
the in vitro data were confirmed in an in vivo model of mouse
systemic infection.
No relationship between biofilm production and PG modifi-
cationswas observed, since the expression ofAmpR-SFO-1,OXA-
24, and OXA-10-like genes decreased biofilm production in the
sameway as the TEM-1-lactamase, withwhich no changes in the
PG were observed. The decreased in biofilm formation has previ-
ously been attributed to the presence of class A and class D -lac-
tamases, specifically TEM-1 and OXA-3 (18). It has been hypoth-
esized that the biofilm phenotypes of class A and class D
-lactamase-expressing transformants may be brought about by
the ability of these -lactamases to bind to or to modify PG (18),
although this was not demonstrated in our model.
In conclusion, the expression of some specific -lactamases
may be associated with changes in the cell wall of the bacterial
host, which are translated into a loss of fitness in vivo and in vitro.
This may explain the “natural” selection of -lactamases in a spe-
cific bacterial genus and may provide important data regarding
the epidemiology of -lactamases and the low rate of isolation in
specific genus. Furthermore, the interaction with the PG observed
with some of the -lactamases studied, such as the AmpR-SFO-1,
OXA-10-like, and OXA-24 -lactamases, supports the hypothesis
that the PBPs and -lactamases have evolved from a common
gene ancestor (27).
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